A picture taken on July 25, 2017 shows Sudanese patient undergoing radiotherapy for cancer treatment, at the Radiation and Isotopes Centre Khartoum (RICK) in the capital Khartoum.AFP / ASHRAF SHAZLY
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors.Kite's portfolio of potential treatments includes one for the blood cancer lymphoma that could receive U.S. regulatory approval later this year.Gilead has developed top-selling treatments for HIV and the liver-destroying hepatitis C virus, but leaders of the biotechnology company told analysts Monday that its push into oncology has been largely nascent so far.The companies expect approval for Kite's potential treatment of refractory aggressive non-Hodgkin lymphoma in the fourth quarter in the U.S. and next year in Europe.
FOLLOW THIS ARTICLE